



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : +91-7045456789 / 7046456789  
Web: [www.samratpharmachem.com](http://www.samratpharmachem.com)

CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Email: [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)

**January 30, 2023**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Ref: Scrip Code: 530125**

Dear Sir/Madam,

**Sub: Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Please find enclosed the intimation letter dated January 30, 2023, received from our Registrar and Share Transfer Agent, Link Intime India Private Limited, providing information regarding issue of duplicate share certificates to the shareholder(s) of the Company.

The information is being submitted pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the same on your records.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary and Compliance Officer**

## Samrat Pharmachem Limited

---

**From:** Aarya Patankar <aarya.patankar@linkintime.co.in>  
**Sent:** 30 January 2023 14:41  
**To:** 'Samrat Pharmachem Limited'  
**Cc:** 'manasi.kandalkar'; nikita.jirepatil@linkintime.co.in; 'Aqueel Mulla'  
**Subject:** RE: Duplicate\_ Samrat\_ 0015137  
**Attachments:** TN23.pdf

Dear Sir,

Please find the attached Duplicate Register for the below mentioned Duplicate request.  
Folio: 0015137

Thanks & Regards,

**LINK**Intime

**Aarya Patankar**

Associate - Client relation Link Intime India Pvt. Ltd

**P:** +91 22 49186000 (Extn: 2322) **M:** +91 9082237936 **F:** +91 22 49186060

**E:** [aarya.patankar@linkintime.co.in](mailto:aarya.patankar@linkintime.co.in) **W:** [www.linkintime.co.in](http://www.linkintime.co.in)

Our Product Offerings



---

**From:** Samrat Pharmachem Limited [mailto:contact@samratpharmachem.in]  
**Sent:** Saturday, January 28, 2023 14:24  
**To:** 'Aarya Patankar' <aarya.patankar@linkintime.co.in>  
**Cc:** 'manasi.kandalkar' <manasi.kandalkar@linkintime.co.in>; nikita.jirepatil@linkintime.co.in; contact@samratpharmachem.in; 'Aqueel Mulla' <aqueelmulla@gmail.com>  
**Subject:** RE: Duplicate\_ Samrat

Approval date: 30/01/2023

Best Regards,

**Sheetal**  
**Samrat Pharmachem Limited**

---

**From:** Aarya Patankar [mailto:[aarya.patankar@linkintime.co.in](mailto:aarya.patankar@linkintime.co.in)]  
**Sent:** 27 January 2023 11:13  
**To:** 'Samrat Pharmachem Limited' <[contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)>

Cc: 'manasi.kandalkar' <[manasi.kandalkar@linkintime.co.in](mailto:manasi.kandalkar@linkintime.co.in)>; [nikita.jirepatil@linkintime.co.in](mailto:nikita.jirepatil@linkintime.co.in)

Subject: Duplicate\_ Samrat

Dear Sir,

Please note we have received 1 duplicate request for Samrat Pharma Ltd form the below mentioned shareholder. Kindly provide approval date for the same.

Shareholder Name : Anantrai Chimanlal Doshi

Client Id : 0015137

Shares : 200

Thanks & Regards,

**LINK**Intime

**Aarya Patankar**

Associate - Client relation Link Intime India Pvt. Ltd

**P:** +91 22 49186000 (Extn: 2322) **M:** +91 9082237936 **F:** +91 22 49186060

**E:** [aarya.patankar@linkintime.co.in](mailto:aarya.patankar@linkintime.co.in) **W:** [www.linkintime.co.in](http://www.linkintime.co.in)

Our Product Offerings



**DISCLAIMER:**

This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the

responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

**DISCLAIMER:**

This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

Samrat Pharmachem Limited  
REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION



FROM: TN23 TO: TN23

SR NO.	FOLIO NO.	SHAREHOLDER'S NAME	FROM	TO	FROM	TO	SHARES	PAID	STUS	Deno	Cert Type	MICR From	MICR To
TN23	0015137	ANANTRAI CHIMANLAL DOSHI											
30/01/2023			10853	10854	1085201	1085400	200	OLD	10.00	DUP		200	
							200						
			30973	30973	1085201	1085400	200	NEW	10.00			200	
							200						

Samrat Pharmachem Limited

REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION

FROM: TN23 TO: TN23

\*\*\*\*\* BATCH CONTROLS\*\*\*\*\*

1. TOTAL NO.OF REQUESTS	:	1
2. TOTAL NO.OF OLD CERTIFICATES	:	2
3. TOTAL NO.OF NEW CERTIFICATES	:	2
4. TOTAL NO.OF PAGES	:	2

\*\*\*\*\* CERTIFICATE (S)CONTROLS\*\*\*\*\*

5. TOTAL NO.OF DUPLICATED CERTIFICATE	:	1
6. TOTAL NO.OF DUPLICATED SHARES	:	200
7. TOTAL NO.OFSUB DIVIDED CERTIFICATE	:	0
8. TOTAL NO.OFSUB DIVIDED SHARES	:	0
9. TOTAL NO.OF CONSOLIDATED CERTIFICATE	:	0
10.TOTAL NO.OF CONSOLIDATED SHARES	:	0